This Article Full Text Full Text (PDF) Submit a related Letter to the Editor Purchase Article View Shopping Cart Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Death, A. K. Articles by Handelsman, D. J. Search for Related Content PubMed PubMed Citation Articles by Death, A. K. Articles by Handelsman, D. J.

Tetrahydrogestrinone Is a Potent Androgen and Progestin

Heart Research Institute (A.K.D.), Camperdown, Sydney, New South Wales 2050, Australia; University of Sydney (A.K.D., K.C.Y.M., D.J.H.), Sydney, New South Wales 2006, Australia; Australian Sports Drug Testing Laboratory (R.K.), Australian Government Analytical Laboratories, Pymble, New South Wales 2073, Australia; and ANZAC Research Institute (D.J.H.), Sydney, New South Wales 2139, Australia

Address all correspondence and requests for reprints to: Professor D. J. Handelsman, ANZAC Research Institute, Sydney, New South Wales 2139, Australia. E-mail: djh{at}anzac.edu.au.

Abstract

Tetrahydrogestrinone (THG) was recently identified as a novel steroid used illicitly to improve athletic performance. Although its structure is closely related to gestrinone, a 19-nor progestin, and resembles that of trenbolone, THG was never marketed, so information on its hormonal properties is not known. In this study, we demonstrate that THG is a highly potent androgen and progestin in a yeast-based in vitro bioassay system expressing human androgen and progesterone receptors. It has no estrogenic activity and no antagonism for any of the three steroid receptor classes.

Footnotes

Abbreviations: AR, Androgen receptor; ER, estrogen receptor; PR, progesterone receptor; THG, tetrahydrogestrinone.

This article has been cited by other articles:

				L. Cantin, F. Faucher, J.-F. Couture, K. P. de Jesus-Tran, P. Legrand, L. C. Ciobanu, Y. Frechette, R. Labrecque, S. M. Singh, F. Labrie, et al. Structural Characterization of the Human Androgen Receptor Ligand-binding Domain Complexed with EM5744, a Rationally Designed Steroidal Ligand Bearing a Bulky Chain Directed toward Helix 12 J. Biol. Chem., October 19, 2007; 282(42): 30910 - 30919. [Abstract] [Full Text] [PDF]

				K. Pereira de Jesus-Tran, P.-L. Cote, L. Cantin, J. Blanchet, F. Labrie, and R. Breton Comparison of crystal structures of human androgen receptor ligand-binding domain complexed with various agonists reveals molecular determinants responsible for binding affinity. Protein Sci., May 1, 2006; 15(5): 987 - 999. [Abstract] [Full Text] [PDF]

				F. Labrie, V. Luu-The, E. Calvo, C. Martel, J. Cloutier, S. Gauthier, P. Belleau, J. Morissette, M.-H. Levesque, and C. Labrie Tetrahydrogestrinone induces a genomic signature typical of a potent anabolic steroid J. Endocrinol., February 1, 2005; 184(2): 427 - 433. [Abstract] [Full Text] [PDF]

				D. J. Handelsman Andro and the Prosteroids: Bolting the Stable Door J. Clin. Endocrinol. Metab., February 1, 2005; 90(2): 1249 - 1251. [Full Text] [PDF]

				D. J. Handelsman Designer Androgens in Sport: When Too Much Is Never Enough Sci. Signal., August 3, 2004; 2004(244): pe41 - pe41. [Abstract] [Full Text] [PDF]